An observational study in Mutations in Exons 18 to 21, sponsored by Provitro GmbH. Completed at 1 site in Germany. Per ClinicalTrials.gov, last updated 2011-06-16.
Sponsored by Provitro GmbH · Observational
While current mutational analyses comprise exons 19 and 21 in which the majority of EGFR-mutations occur, this study aims at investigating the relevance of exon 18 and 20 mutations. Therefore, the investigators analyse 500 routine tumor samples with respect to the above mentioned exons and correlate the results to the clinical outcome. This approach will enable us to potentially identify patients that might in the future benefit from targeted therapy (EGFR-inhibition).
This is the only study on the registry with Provitro GmbH as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Patients who were biopsied and/or received surgery for NSCLC diagnostics
Exclusion Criteria:
This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.